David J Kwiatkowski
Overview
Explore the profile of David J Kwiatkowski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
293
Citations
20936
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rakaee M, Tafavvoghi M, Ricciuti B, Alessi J, Cortellini A, Citarella F, et al.
JAMA Oncol
. 2024 Dec;
11(2):109-118.
PMID: 39724105
Importance: Only a small fraction of patients with advanced non-small cell lung cancer (NSCLC) respond to immune checkpoint inhibitor (ICI) treatment. For optimal personalized NSCLC care, it is imperative to...
2.
Stevering C, Lequin M, Szczepaniak K, Sadowski K, Ishrat S, De Luca A, et al.
Epilepsia
. 2024 Dec;
66(2):356-368.
PMID: 39641935
Objective: Previous retrospective studies have reported vigabatrin-associated brain abnormalities on magnetic resonance imaging (VABAM), although clinical impact is unknown. We evaluated the association between vigabatrin and predefined brain magnetic resonance...
3.
Nassar A, Jayakrishnan R, Feng J, Shepherd F, Adib E, Cheung J, et al.
J Thorac Oncol
. 2024 Sep;
20(1):109-118.
PMID: 39260522
Introduction: Patients with advanced ALK-positive NSCLC typically have poor response to immunotherapy; the benefit of consolidation durvalumab in patients with unresectable stage III ALK-positive NSCLC remains unclear. Herein, we compare...
4.
Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma
Mansfield A, Vivien Yin J, Bradbury P, Kwiatkowski D, Patel S, Bazhenova L, et al.
Lung Cancer
. 2024 Aug;
195:107928.
PMID: 39197359
Purpose: The mesothelin-targeting antibody-drug conjugate anetumab ravtansine was evaluated in combination with the programmed cell death-1 (PD-1) inhibitor pembrolizumab based on the common expression of mesothelin and reports of activity...
5.
Jayakrishnan R, Kwiatkowski D, Rose M, Nassar A
Oncologist
. 2024 Jun;
29(10):833-841.
PMID: 38907669
The genome of a cell is continuously battered by a plethora of exogenous and endogenous processes that can lead to damaged DNA. Repair mechanisms correct this damage most of the...
6.
Ricketts C, de Cubas A, Fan H, Smith C, Lang M, Reznik E, et al.
Cell Rep
. 2024 Apr;
43(4):113063.
PMID: 38578829
No abstract available.
7.
Mekahli D, Muller R, Marlais M, Wlodkowski T, Haeberle S, de Argumedo M, et al.
Nat Rev Nephrol
. 2024 Mar;
20(6):402-420.
PMID: 38443710
Tuberous sclerosis complex (TSC) is an autosomal dominant disorder characterized by the presence of proliferative lesions throughout the body. Management of TSC is challenging because patients have a multifaceted systemic...
8.
Wagner A, Ravi V, Riedel R, Ganjoo K, Van Tine B, Chugh R, et al.
J Clin Oncol
. 2024 Mar;
42(13):1472-1476.
PMID: 38427923
JCO -Sirolimus is approved in the United States for the treatment of metastatic or locally advanced malignant perivascular epithelioid cell tumor (PEComa) on the basis of the primary analysis results...
9.
Bou Farhat E, Adib E, Daou M, Naqash A, Matulonis U, Ng K, et al.
Cancer Cell
. 2024 Feb;
42(2):323.
PMID: 38350424
No abstract available.
10.
Naqash A, Floudas C, Aber E, Maoz A, Nassar A, Adib E, et al.
JCO Precis Oncol
. 2024 Feb;
8:e2300371.
PMID: 38330261
Purpose: Non-small-cell lung cancer (NSCLC) with has inferior outcomes to immune checkpoint inhibitors (ICIs). Using multiomics, we evaluated whether a subtype of NSCLC with a uniquely inflamed tumor immune microenvironment...